Red light, specifically in the deep red wavelength around 670 nanometers, does appear to benefit eye health in meaningful ways. Research shows it can improve age-related declines in color vision, slow nearsightedness progression in children, and even help people with early-stage macular degeneration see better. The key is wavelength, dose, and timing: not all red light exposure is equal, and more is not better.
How Red Light Affects Retinal Cells
Your retina is one of the most energy-hungry tissues in your body. The light-sensing cells that allow you to see colors and fine detail require enormous amounts of cellular energy to function, and that energy production naturally declines with age. By around age 40, the energy output of retinal cells begins to drop, and vision gradually suffers as a result.
Deep red light in the 650 to 800 nanometer range interacts with a specific protein inside your cells’ mitochondria, the structures responsible for producing energy. When red light hits this protein, it speeds up the rate of energy production. In retinal cells, this energy boost can temporarily restore function that has been lost to aging or disease. Think of it like recharging a battery that’s been slowly draining for years.
Improving Color Vision After 40
One of the most striking findings involves a remarkably simple intervention. Researchers at University College London found that just three minutes of exposure to 670-nanometer deep red light in the morning produced an average 17% improvement in color contrast vision in adults aged 34 to 70. Some older participants saw improvements of 20%. All participants had normal eye health before the study, so this wasn’t treating a disease. It was reversing the natural decline in how well aging retinal cells distinguish colors.
The improvement lasted at least a week from a single three-minute session. Critically, three minutes was the sweet spot. That duration worked just as well as a 45-minute exposure, but using the light for hours actually eliminated the benefit entirely. Morning exposure was also essential. The same light applied later in the day had no measurable effect, likely because retinal mitochondria follow a circadian rhythm and are most responsive early in the day.
Slowing Nearsightedness in Children
Childhood myopia (nearsightedness) is a growing global concern, and repeated low-level red light therapy has emerged as one of the more promising interventions. In clinical studies, children who received red light treatments experienced significantly less eye elongation, which is the physical change that drives worsening nearsightedness.
Over 12 months, children treated with red light showed only 0.13 millimeters of axial elongation, compared to 0.38 millimeters in untreated children. Their prescription change was also far smaller: roughly a quarter of a diopter versus nearly a full diopter in the control group. That’s a substantial difference, especially considering that each additional diopter of myopia increases the lifetime risk of serious eye conditions like retinal detachment and glaucoma. The American Academy of Ophthalmology has noted red light therapy as an active area of myopia control research.
Treating Early Macular Degeneration
In 2024, the FDA authorized a light-based therapy for dry age-related macular degeneration (AMD), a progressive condition that gradually destroys central vision. The treatment, called the Valeda Light Delivery System, uses three wavelengths together: yellow (590 nm), red (660 nm), and near-infrared (850 nm). It works by stimulating mitochondrial function in retinal cells, the same basic mechanism seen in the color vision research.
The authorization was based on a study of 100 patients with early and intermediate dry AMD across 10 clinical centers. Patients received nine short treatment sessions over three to five weeks, repeated every four months for two years. After 13 months, 55% of treated eyes gained at least one line of letters on a standard eye chart. Within that group, 20% gained two lines and nearly 6% gained three lines. Treated patients could read an average of five more letters than before, compared to three more letters in the placebo group.
This is a clinical treatment administered by eye care professionals, not something replicated with a consumer device at home. But it represents the first FDA-authorized light therapy for a condition that previously had no treatment options at all.
What Counts as “Red Light”
Not every red light source offers these benefits. The research consistently uses deep red light at very specific wavelengths, primarily around 670 nanometers. A red LED desk lamp or a red-tinted screen filter does not produce concentrated light at this wavelength. Consumer “red light therapy” panels vary widely in their actual output, and many have not been tested for ocular safety or effectiveness.
The wavelength matters because different wavelengths penetrate tissue to different depths and interact with different cellular targets. Shorter red wavelengths (around 620 nm, which look more orange-red) do not have the same effect on the mitochondrial protein responsible for the energy boost. Near-infrared light (around 850 nm), which is invisible to the eye, appears to complement deep red light in clinical settings but works through slightly different pathways.
Risks and Limitations
The safety profile in clinical studies has been reassuring. Participants in the color vision research and the macular degeneration trial did not report significant adverse effects. However, most of these studies involved carefully controlled exposure times and wavelengths. The finding that longer exposure can negate the benefits, or that timing matters so much, underscores that red light therapy is not a “more is better” situation.
Bright light of any kind, including red, can cause retinal damage if exposure is too intense or prolonged. People with existing retinal conditions, light sensitivity, or those taking medications that increase photosensitivity should be cautious with any light-based therapy. The clinical trials for AMD used professional-grade equipment with precise dosing, which is difficult to replicate with consumer devices that may not specify their exact wavelength or power output.
The research is also still young. The color vision improvements, while consistent, have been demonstrated in relatively small studies. The myopia results are promising but come primarily from trials conducted in China, and researchers are working to confirm them across broader populations. The AMD treatment, while FDA-authorized, was studied in only 100 patients, and the difference between treated and placebo groups, though statistically significant, was modest in absolute terms.